New hope for Tough-to-Treat lymphoma: early trial tests Next-Gen cell therapy
NCT ID NCT05741359
Summary
This early-stage study is testing the safety and finding the right dose of a new type of CAR-T cell therapy called BRL-201 for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy involves collecting a patient's own immune cells, genetically modifying them in a lab to better target the cancer, and then infusing them back. The main goals are to see what side effects occur, how severe they are, and to determine the best dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
Contact
-
Tianjin Institute of Hematology
RECRUITINGTianjin, Tianjin Municipality, China
Contact
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.